KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Bristol Myers Squibb (BMY) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Bristol Myers Squibb (BMY) over the last 17 years, with Q4 2025 value amounting to $51.0 million.

  • Bristol Myers Squibb's Other Non Operating Income rose 11672.13% to $51.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$674.0 million, marking a year-over-year increase of 2452.41%. This contributed to the annual value of -$674.0 million for FY2025, which is 2452.41% up from last year.
  • As of Q4 2025, Bristol Myers Squibb's Other Non Operating Income stood at $51.0 million, which was up 11672.13% from $108.0 million recorded in Q3 2025.
  • Bristol Myers Squibb's 5-year Other Non Operating Income high stood at $702.0 million for Q1 2021, and its period low was -$649.0 million during Q1 2022.
  • Its 5-year average for Other Non Operating Income is -$13.2 million, with a median of $26.5 million in 2021.
  • In the last 5 years, Bristol Myers Squibb's Other Non Operating Income tumbled by 1430000.0% in 2022 and then soared by 16363.64% in 2023.
  • Bristol Myers Squibb's Other Non Operating Income (Quarter) stood at -$393.0 million in 2021, then surged by 155.22% to $217.0 million in 2022, then surged by 70.97% to $371.0 million in 2023, then plummeted by 182.21% to -$305.0 million in 2024, then surged by 116.72% to $51.0 million in 2025.
  • Its Other Non Operating Income was $51.0 million in Q4 2025, compared to $108.0 million in Q3 2025 and -$494.0 million in Q2 2025.